Eli Lilly and Co said on Friday said its acute migraine drug, lasmiditan, induced a statistically significant improvement in pain relief against a placebo in a late-stage study.
The trial tested three doses of the oral drug against a placebo. Patients in the trial had an average of more than five migraine attacks per month.
Lilly, which acquired lasmiditan through its $960 million purchase of CoLucid Pharmaceuticals in January, said it plans to file a U.S. marketing application for the drug in the second half of 2018.
About 40 million Americans suffer from migraines, and the disease costs the United States about $36 billion annually in healthcare and lost productivity, according to the Migraine Research Foundation.
(Reporting by Natalie Grover and Divya Grover in Bengaluru; Editing by Sai Sachin Ravikumar)